| Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial S Ramakrishnan, DV Nicolau, B Langford, M Mahdi, H Jeffers, ... The Lancet Respiratory Medicine 9 (7), 763-772, 2021 | 438 | 2021 |
| Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial LM Yu, M Bafadhel, J Dorward, G Hayward, BR Saville, O Gbinigie, ... The Lancet 398 (10303), 843-855, 2021 | 284 | 2021 |
| Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide S Couillard, A Laugerud, M Jabeen, S Ramakrishnan, J Melhorn, T Hinks, ... Thorax 77 (2), 199-202, 2022 | 86 | 2022 |
| Combination fixed‐dose beta agonist and steroid inhaler as required for adults or children with mild asthma I Crossingham, S Turner, S Ramakrishnan, A Fries, M Gowell, F Yasmin, ... Cochrane Database of Systematic Reviews, 2021 | 72 | 2021 |
| Blood eosinophil depletion with mepolizumab, benralizumab, and prednisolone in eosinophilic asthma AM Moran, S Ramakrishnan, CA Borg, CM Connolly, S Couillard, ... American Journal of Respiratory and Critical Care Medicine 202 (9), 1314-1316, 2020 | 45 | 2020 |
| Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis JR Baker, M Mahdi, DV Nicolau, S Ramakrishnan, PJ Barnes, JL Simpson, ... The Lancet Respiratory Medicine 10 (6), 545-556, 2022 | 44 | 2022 |
| Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial PRINCIPLE Collaborative Group, LM Yu, M Bafadhel, J Dorward, ... Medrxiv, 2021.04. 10.21254672, 2021 | 37 | 2021 |
| Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial (Apr, 10.1016/S2213-2600 (21) 00160-0, 2021) S Ramakrishnan, DV Nicolau Jr, B Langford LANCET RESPIRATORY MEDICINE 9 (6), E55-E55, 2021 | 34* | 2021 |
| Standardisation of clinical assessment, management and follow-up of acute hospitalised exacerbation of COPD: a Europe-wide consensus S Ramakrishnan, W Janssens, PR Burgel, M Contoli, FME Franssen, ... International journal of chronic obstructive pulmonary disease, 321-332, 2021 | 25 | 2021 |
| Combination fixed-dose β agonist and steroid inhaler as required for adults or children with mild asthma: a Cochrane systematic review I Crossingham, S Turner, S Ramakrishnan, A Fries, M Gowell, F Yasmin, ... BMJ Evidence-Based Medicine 27 (3), 178-184, 2022 | 20 | 2022 |
| The use of benralizumab in the treatment of near-fatal asthma: a new approach S Ramakrishnan, JR Camp, B Vijayakumar, FM Hardinge, ML Downs, ... American Journal of Respiratory and Critical Care Medicine 201 (11), 1441-1443, 2020 | 14 | 2020 |
| Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled … S Ramakrishnan, H Jeffers, B Langford-Wiley, J Davies, SJ Thulborn, ... The Lancet Respiratory Medicine 12 (1), 67-77, 2024 | 10 | 2024 |
| PRINCIPLE Trial Collaborative Group. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled … LM Yu, M Bafadhel, J Dorward, G Hayward, BR Saville, O Gbinigie, ... Lancet 398 (10303), 843-855, 2021 | 10 | 2021 |
| T5 Point of care blood eosinophil guided oral prednisolone for COPD exacerbations: a multi-centre double blind randomised controlled trial (The STARR2 trial) S Ramakrishnan, H Jeffers, B Langford-Wiley, J Davies, M Mahdi, ... Thorax 77 (Suppl 1), A3-A4, 2022 | 7 | 2022 |
| Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med S Ramakrishnan, DV Nicolau, B Langford | 5 | 2021 |
| Prednisolone for COPD exacerbations: time for a rethink S Ramakrishnan ERJ Open Research 9 (5), 2023 | 4 | 2023 |
| Antibiotics for asthma attacks: masking uncertainty S Ramakrishnan, S Couillard European Respiratory Journal 58 (1), 2021 | 4 | 2021 |
| Chronic obstructive pulmonary disease: management of chronic disease S Ramakrishnan, M Bafadhel, R Russell Medicine 48 (5), 333-336, 2020 | 4 | 2020 |
| Chronic obstructive pulmonary disease exacerbations: do all roads lead to Rome? S Ramakrishnan, I Gyselinck, M Bafadhel, W Janssens American Journal of Respiratory and Critical Care Medicine 205 (9), 1125-1126, 2022 | 3 | 2022 |
| Recovery of breakthrough asthma attacks treated with oral steroids while on monoclonal antibody therapy: protocol for a prospective observational study (BOOST) I Howell, M Mahdi, M Bafadhel, TSC Hinks, S Ramakrishnan, J Melhorn, ... JMIR Research Protocols 12 (1), e46741, 2023 | 2 | 2023 |
Mona BafadhelUniversity of OxfordVerified email at ndm.ox.ac.uk
